Section 5
Chapter 4,973

Clinical studies on chemo therapy for multiple myeloma 1. response rates and survival times in multiple myeloma treated with melphalan and ifosfamide

Adachi, T.

Okayama Igakkai Zasshi 93(5-6): 507-518


ISSN/ISBN: 0030-1558
Accession: 004972481

Between Jan. 1973 and Dec. 1980, 33 patients were assigned at random to 1 of 3 different chemotherapy regimens: 12 patients received melphalan only (M), 11 were treated with concurrent melphalan and prednisolone (MP) and 10 received ifosfamide only (I). The response rates and survival times of these individuals were compared. The median age at the initiation of treatment was 63 yr, range 37-83 yr. The 60-69 yr age group was the largest. Fifteen (45.5%) were male. The incidence of IgG, IgA and B-J [Bence-Jones] protein only in M-protein type was 60.6, 18.2 and 21.2%, respectively. In all regimens, the response rates (as shown by marked diminishment of plasmacytoma and decrease of bone marrow plasmacytosis below 10%) were high; the calcification or disappearance of bone lytic lesions was low. The frequency of a > 50% reduction of the pretreatment value of M-protein level in M + MP and I therapy was 55.2 and 20.0%, respectively. An analysis of patients, according to the clinical stage reported by Durie and Salmon, demonstrated that patients in stage I + II who received M + MP had a higher response rate and longer survival than those in stage III; there was a significant difference between the survival of the stage I + II group and stage III group (P = 0.02). M + MP therapy apparently was more effective in stage I + II than in stage III.

PDF emailed within 1 workday: $29.90